Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07551570 | Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function | PHASE1 | NOT YET_RECRUITING | 32 | — | — | Apr 30, 2026 | Oct 30, 2026 | Apr 27, 2026 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| Normal Renal Function | EXPERIMENTAL | - |
| Mild Renal Impairment | EXPERIMENTAL | - |
| Moderate Renal Impairment | EXPERIMENTAL | - |
| Severe Renal Impairment | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VC005 Tablets | DRUG | Oral single dose |
Inclusion Criteria: 1. Voluntarily sign the informed consent form prior to the trial, fully understand the trial content, procedures, and possible adverse reactions, and be able to complete the study in accordance with the protocol requirements; 2. Participants (including their partners) are willin...